Medacta Group SA (MOVE.SW) — Quality & forensics
As of 2026-10-06 — refreshed nightly. Closelooknet readings from an investment research diary, not ratings or advice.
The Closelooknet module scores
- Valuation 32
- Quality 59
- Growth 56
- Balance sheet 65
- Cash quality 47
- Capital allocation 45
- Momentum 11
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the MOVE.SW chart & overview
FAQ · from the current data · as of 2026-10-06
Quick answers
What is Medacta Group SA's Closelooknet quality reading?
The composite reads 48/100 across 7 modules, as of 2026-10-06: valuation 32, quality 59, growth 56, balance sheet 65, cash quality 47, capital allocation 45, momentum 11. Closelooknet scores are research diary readings, not ratings or investment advice.
What is Medacta Group SA's Altman Z-Score?
5.08, which sits in the safe zone (above 2.99) as of 2026-10-06. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is Medacta Group SA's Piotroski F-Score?
7 of 9, as of 2026-10-06. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does Medacta Group SA's Beneish M-Score indicate?
-2.59 — below the −1.78 manipulation-risk threshold, as of 2026-10-06. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelooknet universe
then Medical Devices. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- DXCM DexCom Incindustry
- SNN Smith & Nephew SNATS Incindustry
- SHL.DE Siemens Healthineers AGindustry
- PHIA.AS Koninklijke Philips NVindustry
- PACB Pacific Biosciences of Californiaindustry
- TXG 10X Genomics Incindustry
- SOON.SW Sonova H Agindustry
- SECT-B.ST Sectra AB (publ)industry
- CEVI.ST CellaVision ABindustry
- BRKR Bruker Corporationindustry
- BIO Bio-Rad Laboratories Incindustry
- EW Edwards Lifesciences Corpindustry
- GKOS Glaukos Corpindustry
- NVCR Novocure Ltdindustry
- PEN Penumbra Incindustry
- MDT Medtronic PLCindustry
- GMED Globus Medicalindustry
- GEHC GE HealthCare Technologies Inc.industry
- QDEL Quidel Corporationindustry
- PODD Insulet Corporationindustry